CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026.
Covered in this story
What has happened since
- Crispr Therapeutics AG is down 1.1% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Crispr Therapeutics AG
- Citizens JMP: $54.1 → $80 by Sep 2027 · Market Outperform via Investing.com
- Morgan Stanley: $48.4 → $60 by Jul 2027 · Equal Weight via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CRSP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Crispr Therapeutics AG →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.